Details of the Drug Combination

General Information of Drug Combination (ID: DCOM1GF)

Drug Combination Name
DFN-15 Hepzato
Indication
Disease Entry Status REF
Carcinoma Investigative [1]
Component Drugs DFN-15   DM3BF9B Hepzato   DM2AZPP
N.A. N.A.
High-throughput Screening Result Testing Cell Line: RXF 393
Zero Interaction Potency (ZIP) Score: 0.09
Bliss Independence Score: 2.33
Loewe Additivity Score: 0.53
LHighest Single Agent (HSA) Score: 0.69

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DC6352A OVCAR3 Investigative [4]
Adenocarcinoma DC52MGE HT29 Investigative [4]
Lung adenocarcinoma DCAAE55 MDA-MB-231 Investigative [4]
------------------------------------------------------------------------------------

References

1 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT05022901) An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma. U.S.National Institutes of Health.
4 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.